Assembly Biosciences Announces the Closing and Early Termination of Hart-Scott-Rodino Waiting Period for License of Microbiom...
February 21 2017 - 7:05AM
Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage
biotechnology company advancing a new class of oral therapeutics
for the treatment of hepatitis B virus (HBV) infection and novel
oral live biotherapeutics for disorders associated with the
microbiome, today announced it has received early termination of
the waiting period required by the Hart-Scott-Rodino Antitrust
Improvements Act of 1976, closed the transaction and received the
upfront payment from Allergan plc for the research, development,
collaboration and license agreement between the two companies
announced on January 9, 2017 (see 8-K filing dated January 10,
2017).
The agreement provides Allergan with worldwide rights
to preclinical compounds from Assembly’s microbiome
gastrointestinal development programs, including ABI-M201 and
ABI-M301, targeting ulcerative colitis and Crohn's disease, as well
as two additional compounds targeting Irritable Bowel
Syndromes.
About Assembly BiosciencesAssembly Biosciences,
Inc. is a clinical-stage public biotechnology company developing
two innovative platform programs: an HBV program advancing a new
class of oral therapeutics for the treatment of hepatitis B virus
(HBV) infection and a microbiome program developing novel oral live
biotherapeutics designed to address diseases associated with the
microbiome. Assembly’s HBV program is advancing multiple drug
candidates with the aim of increasing cure rates in patients with
chronic HBV. The company's microbiome program consists of a fully
integrated platform that includes a robust strain identification
and selection process, methods for strain isolation and growth
under current Good Manufacturing Practices and a patent-pending
delivery system, GEMICEL®, which allows for targeted oral delivery
of live biologic and conventional therapies to the lower
gastrointestinal tract. Assembly is developing a robust pipeline of
product candidates in multiple disease indications. For more
information, visit www.assemblybio.com.
Forward-Looking Statement The information in
this press release contains forward-looking statements regarding
future events, including statements about the clinical and
therapeutic potential of Assembly’s development programs. Certain
forward-looking statements may be identified by reference to a
future period or periods or by use of forward-looking terminology
such as “intends,” “expected” or "developing." Assembly
intends such forward-looking statements to be covered by the safe
harbor provisions contained in Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended. Actual results or developments may differ
materially from those projected or implied in these forward-looking
statements. More information about the risks and uncertainties
faced by Assembly are more fully detailed under the heading "Risk
Factors" in Assembly’s Annual Report on Form 10-K for the year
ended December 31, 2015, and Quarterly Report on Form 10-Q for the
quarter ending September 30, 2016 filed with the Securities and
Exchange Commission. Except as required by law, Assembly assumes no
obligation to update publicly any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contacts
Assembly Biosciences, Inc.
Investors:
Lauren Glaser
(415) 521-3828
Media:
Barbara Lindheim
(212) 584-2276
barbara@assemblybio.com
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Apr 2023 to Apr 2024